GDC-0449 (Vismodegib) --- Hedgehog Antagonist

Bioss Antibodies

GDC-0449 (Vismodegib) --- Hedgehog Antagonist [879085-55-9]

16

Research Use Only

98.0

Vismodegib (GDC-0449) is a potent and specific hedgehog pathway inhibitor with an IC50 of 3 nM. It has been approved by FDA to treat BCC, and also in multiple clinical trials to treat advanced solid tumors. It blocks the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. It prevents multiple ATP-binding cassette (ABC) transporters. GDC-0449 also exhibited efficacy in medulloblastoma animal models and primary pancreatic cancer xenograft models. It was shown to inhibit cell growth in cisplatin-resistant lung cancer cells.

-20°C

51202000